English
Język Polski
Adaptability of clinical pharmacist led interventions in the management of anemia of chronic renal disease: optimizing care
Girish B S
Srinivasan R
Joel M. Johns
C S Meghana
Abstract
Renal anemia is a common comorbidity in chronic kidney disease (CKD) patients, typically treated with erythropoiesis-stimulating agents (ESAs) like erythropoietin. However, both over- and under-treatment are prevalent. In 2008, the Pharmacy Council of India introduced the Pharm.D course to enhance pharmaceutical care in clinical settings. While extensive studies in other countries highlight the benefits of clinical pharmacists' interventions, Indian research on this topic is limited. This prospective randomized controlled trial included CKD patients not on dialysis, with serum creatinine levels of 2-6 mg/dL and hemoglobin (Hb) levels below 12 g/dL. Participants were divided into three subgroups based on baseline Hb levels: < 10 g/dL (Group I), 10-12 g/dL (Group II), and >12 g/dL (Group III). ESAs and iron supplements were adjusted to maintain Hb levels of 10-12 g/dL. Quality of life was assessed using the Short Form Health Survey-36 questionnaire. Out of 448 participants, those in the pharmacist intervention group showed a significant shift towards Group II by the trial's end, compared to the control group. The study demonstrated a significant improvement in quality of life and physical performance, particularly for those in Group II, indicating that maintaining Hb levels at 10-12 g/dL is optimal for Indian CKD patients. This trial exemplifies the profound impact clinical pharmacists can have on patient care, highlighting their crucial role in improving healthcare outcomes through active participation and targeted interventions in clinical settings.
Keywords:
Chronic Kidney Disease, Anemia Management, Clinical Pharmacists Intervention, Pharmaceutical CareSimilar Articles
- Karolina Księżarczyk, Bartłomiej Sankowski, SELECTED ASPECTS OF PARENTERAL NUTRITION , Prospects in Pharmaceutical Sciences: Vol. 15 No. 4 (2017)
- Bartosz Kózka, Anna Kowalkowska, BENZIMIDAZOLE DERIVATES WITH BIOLOGICAL ACTIVITY , Prospects in Pharmaceutical Sciences: Vol. 15 No. 3 (2017)
- Agnieszka Sienicka, Krzysztof Kubasik, Agata Pisula, The glucagon-like peptide-1 analogues therapy in the non-diabetic patients , Prospects in Pharmaceutical Sciences: Vol. 21 No. 1 (2023)
- Olga Grelewicz, Gabriela Kulbacka, Tomasz Mikuła, Alicja Wiercińska-Drapało, Does testosterone intake affect diagnosing primary HIV infection? , Prospects in Pharmaceutical Sciences: Vol. 21 No. 1 (2023)
- Teresa Żołek, Aleksandra Trzeciak, THE MECHANISM OF ACTION OF INDOLE-3-CARBINOL AND 3,3´-DIINDOLYLMETHANE IN CANCER CHEMOPREVENTION , Prospects in Pharmaceutical Sciences: Vol. 15 No. 2 (2017)
- Dibyajyoti Saha, Satish Kumar Sarankar, Critical review on potentials of ethnopharmacological, ethnomedicinal and traditional practices of Madhuca longifolia (J. Koenig Ex L.) J. F. Macbr. (Family: Sapotaceae) , Prospects in Pharmaceutical Sciences: Vol. 21 No. 2 (2023)
- Mustafa Sevindik, Falah Saleh Mohammed, Imran Uysal, Autism: plants with neuro-psychopharmacotherapeutic potential , Prospects in Pharmaceutical Sciences: Vol. 21 No. 3 (2023)
- Elżbieta Gniazdowska, Edyta Gilant, Katarzyna Buś-Kwaśnik, ICH M10 guideline - a harmonized global approach to bioanalysis , Prospects in Pharmaceutical Sciences: Vol. 21 No. 3 (2023)
- Seda Sultan Sağır, Baturay Sapancı, Imran Uysal, Mustafa Sevindik, A review: nutrition and oral-dental health, phytochemical content, biological activity of Salvadora persica (Miswak) , Prospects in Pharmaceutical Sciences: Vol. 22 No. 2 (2024)
- Adam Piasecki, Non-vitamin K antagonist oral anticoagulants (NOAC) in nonvalvular atrial fibrillation – in-group comparison , Prospects in Pharmaceutical Sciences: Vol. 20 No. 1 (2022)
You may also start an advanced similarity search for this article.
Details
References
Statistics
Authors
Citation rules
Cited by / Share
Licence
This work is licensed under a Creative Commons Attribution 4.0 International License.